A phase I, open-label, multicenteir study to evaluate the safety and activity of rituximab in adults with relapsing-remitting multiple sclerosis (RRMS)

被引：0
作者：
Bar-Or, Amit
Calabresi, Peter
Arnold, Douglas
Markowitz, Clyde
Shafer, Stuart
Kasper, Lloyd
Waubant, Emmanuelle
Gazda, Suzanne
Fox, Robert
Sarkar, Neena
Panzara, Michael
Smith, Craig
机构：
来源：
NEUROLOGY | 2007年 / 68卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A84 / A84
页数：1
相关论文
共 50 条
  • [31] Combination treatment of fingolimod with antidepressants in relapsing-remitting multiple sclerosis patients with depression: a multicentre, open-label study - REGAIN
    Bayas, Antonios
    Schuh, Katrin
    Baier, Monika
    Vormfelde, Stefan Viktor
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2016, 9 (05) : 378 - 388
  • [32] A phase II randomized, placebo-controlled, multicenter trial of rituximab in adults with relapsing remitting multiple sclerosis (RRMS)
    Hauser, Stephen
    Waubant, Emmanuelle
    Arnold, Douglas
    Vollmer, Timothy
    Antel, Jack
    Fox, Robert
    Bar-Or, Amit
    Sarkar, Neena
    Langer-Gould, Annette
    Panzara, Michael
    Smith, Craig
    NEUROLOGY, 2007, 68 (12) : A99 - A100
  • [33] Fatigue, cognition and personality in patients with relapsing-remitting multiple sclerosis (RRMS) - A longitudinal study
    Lang, C.
    Lang, M.
    Flachenecker, P.
    Meissner, H.
    Freidel, M.
    Herbst, H.
    Scholz, E.
    Hofmann, W.
    Schlegel, E.
    Elias, W.
    Gehring, K.
    Eckhardt, U.
    Bergmann, A.
    Reifschneider, G.
    Ries, S.
    Ring, C.
    Schreiber, H.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S179 - S179
  • [34] Symptoms and Physical Activity Among Adults With Relapsing-Remitting Multiple Sclerosis
    Motl, Robert W.
    McAuley, Edward
    Wynn, Daniel
    Suh, Yoojin
    Weikert, Madeline
    Dlugonski, Deirdre
    JOURNAL OF NERVOUS AND MENTAL DISEASE, 2010, 198 (03) : 213 - 219
  • [35] Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity
    Juto, Alexander
    Fink, Katharina
    Al Nimer, Faiez
    Piehl, Fredrik
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 37
  • [36] Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; No evidence of rebound disease activity
    Juto, A.
    Fink, K.
    Al Nimer, F.
    Piehl, F.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 290 - 291
  • [37] Safety and Tolerability of BG-12 in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Analyses From the CONFIRM Study
    Phillips, J. Theodore
    Fox, Robert
    Miller, David
    Kita, Mariko
    Hutchinson, Michael
    Havrdova, Eva
    Raghupathi, Kartik
    Yuan, Huixing
    Novas, Mark
    Viglietta, Vissia
    Dawson, Katherine
    NEUROLOGY, 2012, 78
  • [38] Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis
    Tian, Xin
    Chen, Chaoyang
    Ma, Lingyun
    Wei, Ran
    Li, Min
    Wang, Xiaoqing
    Wu, Ye
    Zhou, Ying
    Cui, Yimin
    JOURNAL OF NEUROIMMUNOLOGY, 2020, 347
  • [39] Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis
    Hu, Yang
    Nie, Hao
    Yu, Hai-Han
    Qin, Chuan
    Wu, Long-Jun
    Tang, Zhou-Ping
    Tian, Dai-Shi
    AUTOIMMUNITY REVIEWS, 2019, 18 (05) : 542 - 548
  • [40] An open-label multi-center safety and efficacy study of oral recombinant ovine interferon tau (IFNt) administered daily in relapsing-remitting multiple sclerosis
    Buckle, Guy J.
    Bourdette, Dennis N.
    Waubant, Emmanuelle
    Kachuck, Norman
    Healy, Brian
    Bakshi, Rohit
    Guttmann, Charles R.
    Weiner, Howard L.
    MULTIPLE SCLEROSIS, 2008, 14 : S161 - S161
12345